GlobeNewswire

Wood Mackenzie Scales Data Analytics Across the Energy Transition by Adding Quinbrook as a Lens Power Development Partner

Share

Lens® decision intelligence platform connects the dots across a rapidly changing energy landscape

LONDON/HOUSTON/SINGAPORE, June 21, 2021 (GLOBE NEWSWIRE) -- Wood Mackenzie, the leading provider of commercial intelligence for the world’s natural resources sector, today welcomes Quinbrook Infrastructure Partners as a development partner for the industry-leading Lens decision intelligence platform.

With its analytics-ready power and renewables data integrated into a single platform, Lens Power enables organisations to maximise investment opportunities in clean energy and be on the forefront of the energy transition.

Wood Mackenzie, a Verisk business (Nasdaq:VRSK), is collaborating with early adopters to design a power solution that provides a holistic understanding of what is happening in the world of energy, allowing organisations to analyse, screen and value assets or companies quickly and confidently to improve profitability and minimise risk.

Global Power Generation Assets byEnergy Source

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

Source: Wood Mackenzie Lens Power

Matt Overbeck, Wood Mackenzie Senior Vice President, Head of Power and Renewables, said: “We’ve been in the power modelling business for a decade and have invested heavily to build out our energy transition division, both organically and through acquisition. We’re delighted to partner with Quinbrook, a specialist investment management firm focused exclusively on low carbon and renewable energy infrastructure investment and operational asset management.”

Quinbrook is widely recognised for making positive contributions towards Environmental, Social and Governance (ESG) investing, winning multiple awards for its Low Carbon Power Fund, and for its role as a value-add investment manager of clean energy infrastructure.

William Blake, Senior Vice President at Quinbrook, said: “Partnering with an established global energy data analytics company like Wood Mackenzie offers us a collaborative and responsive setting to discuss, implement, and improve the data, technology, and tools that aid our evaluation and monitoring of market trends and investment opportunities across the clean energy landscape.

“The energy transition to a zero-carbon future is driving a significant amount of investment opportunity, but it is also spawning new and complex risks for investment managers and market participants to navigate. Identifying, understanding, and actively addressing these risks head-on is fundamental to our approach in creating long-term and resilient asset value for our investors.

“Having access to the Wood Mackenzie Lens Power platform provides us with data-driven insight critical in supporting a disciplined underwriting when allocating our investor’s capital.”

Lens Power, integrating conventional power, solar, wind, energy storage, and hydrogen data sets in an integrated and easy-to-use platform, is attractive to energy players in the financial, utility, manufacturing, and oil and gas sectors.

ENDS

About Wood Mackenzie Lens®
Wood Mackenzie’s Lens® platform is the industry standard in critical decision-support, harnessing the power of big data to provide answers to complex questions, enabling customers to manage their operations, processes, and capital swiftly and efficiently, wherever they are. https://www.woodmac.com/wood-mackenzie-lens-power/

For further information contact:
Laura Hindley
Senior Global PR Manager
laura.hindley@woodmac.com

About Wood Mackenzie
Wood Mackenzie, a Verisk Analytics business, is a trusted source of commercial intelligence for the world's natural resources sector. We empower clients to make better strategic decisions, providing objective analysis and advice on assets, companies, and markets. For more information, visit: www.woodmac.com or follow us on Twitter @WoodMackenzie

WOOD MACKENZIE is a trademark of Wood Mackenzie Limited and is the subject of trademark registrations and/or applications in the European Community, the USA and other countries around the world.

About Quinbrook
Quinbrook Infrastructure Partners (www.quinbrook.com) is a specialist investment manager focused exclusively on lower carbon and renewable energy infrastructure investment and operational asset management in the U.S., U.K. and Australia. Quinbrook is led and managed by a senior team of power industry professionals who have collectively invested over US $8 billion of equity in energy infrastructure assets since the early 1990s, representing a total enterprise value of US $28.7 billion or 19.5 GW of power supply capacity. Quinbrook's investment and asset management team has offices in Houston, London, Jersey, and the Gold Coast of Australia. Quinbrook's global investment and portfolio company teams are actively developing and constructing a portfolio exceeding 17GW of onshore wind, solar PV, reserve peaking power, battery storage projects, grid support infrastructure, Virtual Power Plants and Community Energy Networks across the U.S., U.K., and Australia.

About Verisk
Verisk (Nasdaq:VRSK) provides predictive analytics and decision support solutions to customers in the insurance, energy and specialized markets, and financial services industries. More than 70 percent of the FORTUNE 100 relies on the company’s advanced technologies to manage risks, make better decisions and improve operating efficiency.

The company’s analytic solutions address insurance underwriting and claims, fraud, regulatory compliance, natural resources, catastrophes, economic forecasting, geopolitical risks, as well as environmental, social and governance (ESG) matters. Celebrating its 50th anniversary, the company continues to make the world better, safer and stronger, and fosters an inclusive and diverse culture where all team members feel they belong. With more than 100 offices in nearly 35 countries, Verisk consistently earns certification by Great Place to Work.

For more: Verisk.comLinkedInTwitterFacebook and YouTube.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Boyden Welcomes Healthcare & Life Sciences Expert Stephen Irish as Managing Partner, Japan4.8.2021 20:00:00 CEST | Press release

Long-term specialist in senior-level recruitment in Japan and Asia/Pacific joins Boyden as head of the Japan office and member of Boyden’s global healthcare & life sciences practice TOKYO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, is delighted to welcome Stephen Irish as Managing Partner and head of Boyden Japan. Based in Tokyo, Irish joins Boyden’s global healthcare & life sciences practice, leading senior level searches for clients in Japan and Asia/Pacific, as well as those headquartered outside the region. “Japan is a unique market, and requires specialist knowledge and understanding of the cultural nuances at the individual, organisational and government level,” commented Stephen Irish, Managing Partner, Boyden Japan. “Having worked with Japanese companies throughout my career, I am delighted to bring this experience into a collaborative, international environment with Boyden. For clients

Novo Nordisk's net profit increased by 10% in the first six months of 20214.8.2021 16:41:41 CEST | Press release

4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER).In June 2021, Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from the US Food and Drug Administration (FDA) for weight management in adults living with obesity.For the 2021 outloo

Novo Nordisk's net profit increased by 10% in the first six months of 20214.8.2021 16:23:58 CEST | Press release

4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER).In June 2021, Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from the US Food and Drug Administration (FDA) for weight management in adults living with obesity.For the 2021 outloo

Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting4.8.2021 15:00:00 CEST | Press release

Press release, Helsinki, 4 August 2021 at 4 PM(EEST) Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it will be exhibiting during the annual meeting of the Texas Association of Neurological Surgeons this week, August 5-8, 2021 at the Hyatt Regency Lost Pines Resort & Spa in Lost Pines, Texas. This meeting continues to be a significant opportunity for Nexstim to engage current and prospective users of the Nexstim system. Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a

ProMIS Neurosciences Issues Chairman’s Memorandum4.8.2021 13:30:00 CEST | Press release

Notes and comments after the first AAIC meeting in the era of approved disease-modifying therapies for Alzheimer’s Disease TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairman’s memorandum, commenting on highlights of the recent 2021 Alzheimer’s Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting. “We are in a new era in the fight against Alzheimer’s, ALS, and other neurodegenerative diseases,” stated Eugene Williams, Executive Chairman of ProMIS Neurosciences. “ProMIS and many others have predicted this development and we believe that the Alzheimer’s community will look back on 2021 as a turning point, just as 2010 was a turnin

Aspo Plc will publish its Half year financial report on August 11, 20214.8.2021 12:00:00 CEST | Press release

Aspo Plc Press Release August 4, 2021 at 1 p.m. Aspo Plc will publish its Half year financial report on August 11, 2021 Aspo Plc will publish its Half year financial report for January–June 2021 on Wednesday, August 11, 2021 at approximately 9:30 a.m. EEST. The press conference for analysts, investors and media will be held on Wednesday, August 11, 2021 at 2 p.m. The Half year financial report will be presented by CEO Aki Ojanen. The press conference will be held in Finnish and it can be followed at https://aspo.videosync.fi/2021-q2-results, or by calling +358 9 817 10310 (12219443#) 5 to 10 minutes before the beginning of the press conference. The recording of the event will be available on the company’s website later on the same day. Presentation material will be available at www.aspo.com before the event. Aspo Plc Aki Ojanen CEO For further information, please contact: Keijo Keränen, Group Treasurer, +358 400 955 821, keijo.keranen@aspo.com DISTRIBUTION: Key media www.aspo.com Aspo

Cortus Energy: Sista dag för handel med betalda tecknade units (BTU) och omvandling till aktier och teckningsoptioner av serie TO8 och TO94.8.2021 09:46:34 CEST | Pressemelding

PRESSMEDDELANDE Stockholm, den 4 augusti 2021 Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) har som tidigare kommunicerats genomfört en övertecknad företrädesemission av units om cirka 64,8 MSEK ("Företrädesemissionen"). Företrädesemissionen är nu registrerad hos Bolagsverket ochsista dag för handel med BTU är fredagenden 6augusti 2021. Avstämningsdag för omvandlingen är den 10augusti 2021, varefter BTU kommer att omvandlas till aktier och teckningsoptioner av serie TO8 och TO9. Aktier och teckningsoptioner som tecknades i Företrädesemissionen förväntas vara tillgängliga på tecknarens depå/vp-konto den 12 augusti 2021. Första handelsdag för teckningsoptionerna i serie TO8 och TO9 förväntas vara den 13 augusti 2021. Teckningsoptioner av serie TO8 Teckning av aktier med stöd av teckningsoptioner av serie TO8 sker under perioden från och med den 16 november 2021 till och med den 29 november 2021. Varje teckningsoption av serie TO8 ger rätt att teckna en (1) ny aktie i Bolaget mot kon